Table 3.
Inputs in the CE model.
| Base case | DSA Rangea | Distribution | Source | |
|---|---|---|---|---|
| Relative risks of mortality | ||||
| ≥53 seizures/year | 10.16 | 2.94–35.18 | – | (30) |
| 13–52 seizures/year | 8.64 | 2.88–25.93 | – | (30) |
| ≤ 12 seizures/year | 7.21 | 2.52–20.6 | – | (30) |
| Drug costs per 4 months ($) | ||||
| PER 4 mg/day | 878 | ±10% | Gamma | MENET, 335 clinical trial |
| AEDs – PER 4 mg/day group | 692 | −20%−0% | Gamma | |
| PER 8 mg/day | 1,754 | ±10% | Gamma | MENET, 335 clinical trial |
| AEDs – PER 8 mg/day group | 827 | −20–0% | Gamma | |
| LCM 200 mg/day | 1,484 | −20–0% | Gamma | MENET, (16) |
| AEDs – LCM 200 mg/day group | 695 | −20–0% | Gamma | |
| LCM 400 mg/day | 2,968 | −20–0% | Gamma | MENET, (16) |
| AEDs – LCM 400 mg/day group | 549 | −20–0% | Gamma | |
| Medical costs per 4 months ($) | ||||
| ≥53 seizures/year | 571 | ±20% | Gamma | Health care documentsb, KOL |
| 13–52 seizures/year | 441 | ±20% | Gamma | Health care documents, KOL |
| ≤ 12 seizures/year | 273 | ±20% | Gamma | Health care documents, KOL |
| Seizure free | 180 | ±20% | Gamma | Health care documents, KOL |
| Health Utilities per 4 months | ||||
| ≥53 seizures/year | 0.619 | ±0.15 | Beta | (31) |
| 13–52 seizures/year | 0.628 | ±0.12 | Beta | (31) |
| ≤ 12 seizures/year | 0.673 | ±0.14 | Beta | (31) |
| Seizure free | 0.711 | ±0.14 | Beta | (31) |
a
To echo the medical pricing reform in China, we assumed the drug prices could only decrease and the service item prices increase. In addition, we assumed a narrower range (±10%) of Perampanel price according to the lowest price provided by Eisai Co., Ltd.
b
The health care documents from the 9 provinces medical security bureaus.
CE, cost-effectiveness; DSA, deterministic sensitivity analysis; PER, perampanel; LCM, lacosamide; AED, antiepileptic drug.